Lisa Depestel

Lisa Depestel

Auto-generated profile, based on publicly available information

Lisa Depestel

Pediatric Precision Oncology Lab (PPOL), Department of Biomolecular Medicine, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Science Advances
Verified
Journal Article
Open access
CNCarolina Nunes
Carolina Nunes
LDLisa Depestel
Lisa Depestel
LMLiselot Mus
Liselot Mus
KKKaylee M. Keller
Kaylee M. Keller
LDLouis Delhaye
Louis Delhaye
FSFrank Speleman
Frank Speleman
High-risk neuroblastoma, a pediatric tumor originating from the sympathetic nervous system, has a low mutation load but highly recurrent somatic DNA copy number variants. Previously, segmental gains and/or amplifications allowed identification of drivers for neuroblastoma development. Using this approach, combined with gene dosage impact on expression and survival, we identified ribonucleotide reductase subunit M2 (RRM2) as a candidate dependency factor further supported by growth inhibition upon in vitro knockdown and accelerated tumor formation in a neuroblastoma zebrafish model coexpressing human RRM2 with MYCN. Forced RRM2 induction alleviates excessive replicative stress induced by CHK1 inhibition, while high RRM2 expression in human neuroblastomas correlates with high CHK1 activity. MYCN-driven zebrafish tumors with RRM2 co-overexpression exhibit differentially expressed DNA repair genes in keeping with enhanced ATR-CHK1 signaling activity. In vitro, RRM2 inhibition enhances intrinsic replication stress checkpoint addiction. Last, combinatorial RRM2-CHK1 inhibition acts synergistic in high-risk neuroblastoma cell lines and patient-derived xenograft models, illustrating the therapeutic potential.

20 March 2019 in BMC Genomics
Verified
Journal Article
Open access
PDF file
SLSiebe Loontiens
Siebe Loontiens
LDLisa Depestel
Lisa Depestel
SVSuzanne Vanhauwaert
Suzanne Vanhauwaert
GDGivani Dewyn
Givani Dewyn
CGCharlotte Gistelinck
Charlotte Gistelinck
KDKaat Durinck
Kaat Durinck
Transgenic zebrafish lines with the expression of a fluorescent reporter under the control of a cell-type specific promoter, enable transcriptome analysis of FACS sorted cell populations. RNA quality and yield are key determinant factors for accurate expression profiling. Limited cell number and FACS induced cellular stress make RNA isolation of sorted zebrafish cells a delicate process. We aimed to optimize a workflow to extract sufficient amounts of high-quality RNA from a limited number of FACS sorted cells from Tg(fli1a:GFP) zebrafish embryos, which can be used for accurate gene expression analysis. We evaluated two suitable RNA isolation kits (the RNAqueous micro and the RNeasy plus micro kit) and determined that sorting cells directly into lysis buffer is a critical step for success. For low cell numbers, this ensures direct cell lysis, protects RNA from degradation and results in a higher RNA quality and yield. We showed that this works well up to 0.5× dilution of the lysis buffer with sorted cells. In our sort settings, this corresponded to 30,000 and 75,000 cells for the RNAqueous micro kit and RNeasy plus micro kit respectively. Sorting more cells dilutes the lysis buffer too much and requires the use of a collection buffer. We also demonstrated that an additional genomic DNA removal step after RNA isolation is required to completely clear the RNA from any contaminating genomic DNA. For cDNA synthesis and library preparation, we combined SmartSeq v4 full length cDNA library amplification, Nextera XT tagmentation and sample barcoding. Using this workflow, we were able to generate highly reproducible RNA sequencing results. The presented optimized workflow enables to generate high quality RNA and allows accurate transcriptome profiling of small populations of sorted zebrafish cells.

18 November 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SKSimon Krols
Simon Krols
MRMuhammad Rishfi
Muhammad Rishfi
FMFien Martens
Fien Martens
AHAnouk Van Hauwermeiren
Anouk Van Hauwermeiren
ESEllen Sanders
Ellen Sanders
SCSerge Van Calenbergh
Serge Van Calenbergh
Aurora kinase A (AURKA) is an established oncogenic factor and therapeutic target in neuroblastoma due to its roles in mitosis and stability of the MYCN protein. We previously identified SK2188 as a highly potent, selective, and fast-acting AURKA degrader capable of inducing MYCN destabilization. However, SK2188 showed low systemic exposure and rapid clearance in mice, necessitating further chemical optimization. Here, we describe our structure–activity optimization efforts involving linker rigidification and incorporation of alternative cereblon- and AURKA-recruiting ligands, leading to two optimized PROTACs, SK4454 and SK5527. Both compounds retained rapid and selective AURKA degradation with improved pharmacokinetic properties. Importantly, single intravenous administration of either degrader efficiently reduced AURKA levels in vivo in a neuroblastoma xenograft mouse model. Moreover, MDR1-mediated PROTAC efflux was identified as a key intrinsic mechanism limiting in vitro potency. These results establish SK4454 and SK5527 as advanced AURKA degraders with improved pharmacokinetic properties, warranting further preclinical evaluation.

26 June 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
SLSiebe Loontiens
Siebe Loontiens
SVSuzanne Vanhauwaert
Suzanne Vanhauwaert
LDLisa Depestel
Lisa Depestel
GDGivani Dewyn
Givani Dewyn
WLWouter Van Loocke
Wouter Van Loocke
FSFrank Speleman
Frank Speleman

25 February 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
INIris H. Nelen
Iris H. Nelen
SLSoetkin Leys
Soetkin Leys
SBSarah-Lee Bekaert
Sarah-Lee Bekaert
FVFanny De Vloed
Fanny De Vloed
FMFien Martens
Fien Martens
KDKaat Durinck
Kaat Durinck
Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signaling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma (NB), in keeping with its role in RS resistance. We identified strong synergism for combined RRM2-CHK1 inhibition using the iron chelator triapine and prexasertib respectively. To obtain direct RNR targeting, we evaluated a novel inhibitor, TAS1553, specifically disrupting the RNR complex in this study. Treatment with TAS1553 impedes cell growth and induces enhanced RS, DNA damage and apoptosis. We demonstrated strong synergism between TAS1553 and the CHK1 inhibitors prexasertib and SRA737 in both NB cell lines and tumoroids as well as in sarcoma cell lines. We confirm drug synergism in vivo in a NB zebrafish xenograft model, further underscoring the broad clinical potential of combinatorial RRM2-CHK1 inhibition. Altogether, this study paves the way for further preclinical testing of second generation RRM2 and CHK1 inhibitors such as TAS1553 and SRA737 in neuroblastoma and sarcomas.

11 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
LDLouis Delhaye
Louis Delhaye
DRDries Rombaut
Dries Rombaut
EBEric de Bony
Eric de Bony
EDEva D’HAene
Eva D’HAene
TBTiago França Brazao
Tiago França Brazao
PMPieter Mestdagh
Pieter Mestdagh
Neuroblastoma is a pediatric cancer of the sympathetic nervous system characterized by heterogeneous cell states that mirror normal differentiation trajectories. Each state is governed by a core regulatory transcriptional circuitry that reinforces cell identity through an autoregulatory feedforward loop. We identified the long non-coding RNA NESPR as specifically expressed in adrenergic neuroblastoma cells. NESPR expression correlates with high-risk neuroblastoma clinical parameters and poor patient survival. NESPR is located within an insulated gene neighborhood alongside PHOX2B, a master transcription factor of the adrenergic identity. NESPR depletion reduced cell proliferation and increased caspase activity in neuroblastoma cell lines, and NESPR knockout in a neuroblastoma zebrafish model led to reduced tumor penetrance. Subcellular localization revealed NESPR to be a cytosolic long non-coding RNA, suggesting a trans -regulatory function. RNA-sequencing following NESPR depletion revealed a shift from an adrenergic to a mesenchymal cell state, due to proteotoxic stress-induced molecular reprogramming. These findings suggest NESPR as a regulator of neuroblastoma cell identity with potential therapeutic opportunities in high-risk neuroblastoma cases.